S9E13: Our Chat with Crinetics CEO Dr. Scott Struthers.

<p>Today, Dr. Scott Struthers talks to PWN about paltusotine, their new once-a-day <a href='https://pituitaryworldnews.org/category/acromegaly/'>acromegaly</a> oral drug candidate. <a href='https://crinetics.com/'>Crinetics</a> recently <a href='https://pituitaryworldnews.org/big-news-for-acromegaly/'>published results</a> from the latest phase of the paltusotine clinical trial. He discussed the results and provided a fascinating look at the details and their learning from the data as they analyzed these initial results. He also shared the status of a new drug for <a href='https://crinetics.com/pipeline/'>Cushing's and Congenital Adrenal Hyperplasia (CAH)</a>, currently entering phase 2 of a clinical trial. Don't miss it!  </p> <p>For those following PWN, you may recall we recorded <a href='https://pituitaryworldnews.org/podcast-looking-world-new-drug-discovery-development/'>our first podcasts with Dr. Struthers </a>when paltusotine entered its clinical trial in 2017. If you haven't heard it, I highly recommend it. It is really interesting to hear Dr. Struthers talk about their work on drugs for acromegaly and other neuroendocrine disorders and how the company has progressed since those early days. Also, if you'd like to learn more, <a href='https://pituitaryworldnews.org/exploration-innovation-and-creativity-an-intimate-look-at-new-drug-development-in-the-world-of-pituitary-and-neuroendocrine-disease/'>listen to our podcast series on new drug development</a>, "The Journey to a New Drug."</p> <p> </p>